Tessa Therapeutics is a clinical stage biopharmaceutical company focused on the development and commercialization of cancer immunotherapies. Our goal is to bring hope to cancer patients with no viable treatment options. Today, we are a leader in Virus-Specific T cell therapy and are conducting the world’s first FDA Phase III T cell therapy trial in a solid tumor indication.
The immuno suppressive tumor microenvironment presents significant obstacles to the treatment of solid tumors with immunotherapy. Our Virus-Specific T cell (VST) technology overcomes these barriers and has shown promising clinical success.
We have a broad clinical pipeline targeting multiple cancer indications. Our lead product is currently in a multi-centre international Phase III trial and our Phase I trial targeting cervical and oropharyngeal cancer has demonstrated early clinical significance with minimal toxicities.
We are committed to working towards our vision of a world without untreatable cancers. We are constantly advancing our deep understanding of the body’s immune system to design next-generation VST therapies which demonstrate persistence, durability, and tumor penetration with minimal side effects for patients. Visit our patients page to know more about our therapies, ongoing clinical trials and potential treatment process.
August 13, 2018
Tessa Therapeutics featured on CNBC Capital Connection
Tessa on Twitter
Congratulations to our CMO, Dr Toh Han Chong, on receiving the 2018 National Outstanding Clinician Scientist Award at the National Medical Excellence Awards. Dr Toh has been recognized by @sporeMOH for outstanding contributions in #cancer #immunotherapy. #TopOfTessa https://t.co/Q8MHWgBh0g
Tessa Therapeutics featured on @CNBC Capital Connection: Our CFO, Desmond Lim ( @kaiserdesmond), spoke to @NancyCNBC about Tessa’s plans for the future and the promise of Virus-Specific T cell ( #VST) #cancer #immunotherapy. Watch the full interview here: https://t.co/nFaTzyE0rw. https://t.co/43gQ9YGd6K